In Portugal’s wild northern borderlands, survival and spirituality go hand in hand with the changing seasons, as they have ...

In the heart of Rapa Nui, better known as Easter Island, a species long thought lost is taking root once again. The toromiro ...

The highly biodiverse Brazilian Atlantic Forest has a long history of deforestation and only a small portion of the original forest remains. This study examines the spatial and temporal patterns ...

Porto Novo Business Private Limited is an Indian Non-Government Company. It's a private company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 1.0 lakhs and ...

Current local time in Porto-Novo (Africa/Porto-Novo timezone). Get information about the Africa/Porto-Novo time zone. Local time and date, DST adjusted (where ever daylight saving time is applicable) ...

The director of more than 20 films, including Xica da Silva and Bye Bye Brazil, Diegues was a leading figure in Cinema Novo, a movement that emerged in the 1960s and used film to critique social ...

He was 84. The director of more than 20 films, including “Xica da Silva” and “Bye Bye Brazil,” Diegues was a leading figure in Cinema Novo, a movement that emerged in the 1960s and used ...

Novo Nordisk (NVO) shares gain after the pharmaceutical company's earnings beat on the bottom and top lines despite warnings of slower growth. Novo Nordisk CEO Lars Fruergaard Jørgensen sits down ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

The question of trees and Net Zero is often a thorny one. Which trees, where? Is woodland regeneration better than planting? And, more importantly, is the whole thing part of a carbon credit ...

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...